

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12Q 1/68, A61P 43/00, A61K 31/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/34515</b> <b>(43) International Publication Date:</b> 15 June 2000 (15.06.00)
<b>(21) International Application Number:</b> PCT/GB99/03973 <b>(22) International Filing Date:</b> 30 November 1999 (30.11.99)  <b>(30) Priority Data:</b> 9826747.9 5 December 1998 (05.12.98) GB  <b>(71) Applicant (for all designated States except US):</b> AS-TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ANAND, Rakesh [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). MORTEN, John, Edward, Norris [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SMITH, John, Craig [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).  <b>(74) Agent:</b> BILL, Kevin; Global Intellectual Property, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> USE OF FACTOR X POLYMORPHISM IN THE DIAGNOSIS AND TREATMENT OF FACTOR X AND/OR FACTOR XA MEDIATED DISEASES		
<b>(57) Abstract</b> <p>This invention relates to polymorphisms in the human Factor X gene, in particular to the discovery of two single nucleotide polymorphisms in the coding sequence of the human Factor X gene. The invention also relates to methods and materials for analysing allelic variation in the Factor X gene, and to the use of Factor X polymorphism in the diagnosis and treatment of Factor X and/or Factor Xa-mediated diseases, such as thrombotic diseases.</p>		